ACTEMRA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION

Manufacturer
F.HOFFMANN-LA ROCHE LTD(SWITZERLAND)

Registraction Number
MAL20091983ACRZ

Content:
ACTEMRA 20 mg/ml Concentrate for Solution for Infusion contains Tocilizumab 20 mg/ml as the active ingredient. Tocilizumab is an interleukin-6 (IL-6) receptor antagonist used to treat various inflammatory conditions.
Indications:

• Rheumatoid Arthritis (RA): For adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
• Giant Cell Arteritis (GCA): For adult patients with GCA.
• Polyarticular Juvenile Idiopathic Arthritis (PJIA): For patients 2 years of age and older with active PJIA.
• Systemic Juvenile Idiopathic Arthritis (SJIA): For patients 2 years of age and older with active SJIA.
• Cytokine Release Syndrome (CRS): For adults and pediatric patients 2 years of age and older with severe or life-threatening CRS induced by CAR T-cell therapy.
• COVID-19: Tocilizumab is indicated for the treatment of COVID-19 in certain cases.

• Dosage: The dosage varies based on the condition being treated and patient response. For RA, the recommended starting dose is 4 mg per kg every 4 weeks, which can be increased to 8 mg per kg every 4 weeks based on clinical response.
• Administration: Administer intravenously (IV) or subcutaneously (SC) as directed by a healthcare provider.
• Precautions: Monitor for infections, as serious infections have occurred in patients receiving ACTEMRA. Perform tests for latent tuberculosis (TB) before starting treatment. Inform your doctor of any other medications or health conditions.
• Storage: Store below 30°C, away from moisture and heat.